DEF: Allurion Seeks Shareholder Approval for Key Strategic Moves

Allurion Technologies, Inc. is seeking stockholder approval for a reverse stock split, an amended equity incentive plan, option repricing, and the issuance of shares for debt conversion to address NYSE listing requirements and enhance long-term value.

Summary

• The company is holding its Annual Meeting of Stockholders on December 18, 2025, virtually via live audio webcast.
• Stockholders will vote on eight proposals, including the election of three Class II Directors (Dr. Omar Ishrak, R. Jason Richey, Douglas Hudson) and the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2025.
• A key proposal is to amend and restate the 2023 Stock Option and Incentive Plan, increasing the authorized share pool to approximately 9,987,474 shares (20% of fully-diluted shares outstanding post-Exchange) and lowering the non-employee director compensation limit from $750,000 to $350,000 annually.
• The company proposes a one-time repricing of certain outstanding stock options (Eligible Options) granted under the 2023 Plan, covering up to 110,990 shares, to restore incentive and retention value due to a significant decline in stock price.
• Stockholder approval is sought for the issuance of common stock upon conversion of Series B convertible preferred stock, which will be issued to RTW in exchange for outstanding debt and revenue interest obligations, aiming to increase stockholders' equity and aid NYSE listing compliance.
• Approval is also requested for the issuance of common stock upon the exercise of certain private placement warrants, which were issued in a November 2025 private placement that generated $5.0 million in gross proceeds.
• A reverse stock split is proposed, with a ratio between 1-for-1.5 and 1-for-20, to increase the per-share trading price and appeal to a broader range of investors, as well as support continued NYSE listing.
• An adjournment proposal is included, if necessary, to permit further solicitation of proxies for Proposals 3, 4, 5, 6, and 7.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While the company is proactively addressing significant challenges (NYSE listing non-compliance, underwater options, debt burden) through strategic proposals like a reverse stock split, option repricing, and debt-to-equity conversion, these actions themselves highlight underlying financial and market perception issues. The potential for dilution and the uncertainty of the market's reaction to these measures temper any positive outlook from the proactive steps.

Positives

• The proposed Plan Amendment aims to attract, motivate, and retain talented employees, which is critical given the company's focus on managing cash burn and a general freeze on base salaries and cash bonuses since 2022.
• The Option Repricing is designed to restore the incentive and retentive value of 'underwater' stock options for employees and consultants, aligning their interests with stockholders without incurring significant additional dilution or cash expenditures.
• The Preferred Shares Issuance and Exchange Agreement with RTW will convert outstanding indebtedness into equity, substantially increasing stockholders' equity and providing a significant pathway to regain compliance with NYSE listing requirements.
• The Reverse Stock Split is intended to raise the per share trading price, making the common stock more attractive to institutional investors and potentially improving market liquidity and perception.
• The company has adopted a Compensation Recovery Policy (clawback policy) and its equity plans are administered by independent directors, reflecting good corporate governance practices.

Negatives

• The company's stock price has experienced a significant decline, leading to outstanding stock options being 'underwater' with a weighted average exercise price of $61.68 compared to a market value of $1.85 per share as of the Record Date.
• The company received a Market Cap Notice from the NYSE on August 29, 2024, indicating non-compliance with the Minimum Market Capitalization Standard ($50.0 million average over 30 trading days and stockholders' equity below $50.0 million).
• The issuance of common stock upon conversion of Series B Preferred Stock and exercise of Private Placement Warrants will have a dilutive effect on current stockholders, reducing their percentage ownership and potentially causing a decline in market price.
• Failure to obtain stockholder approval for the Preferred Shares Issuance would prevent the Exchange from being consummated, leaving the company with existing debt obligations and making NYSE listing compliance less likely.
• The Reverse Stock Split carries risks, including the possibility that it may not result in a sustained increase in trading price, could be viewed negatively by some investors, and may increase the proportion of unissued authorized shares, potentially having anti-takeover effects.

Risks

• The Reverse Stock Split may not result in a sustained increase in the trading price of common stock, as other factors like financial results and market conditions can still adversely affect the price.
• The Reverse Stock Split could negatively impact market liquidity due to a reduced number of outstanding shares and may increase the number of stockholders owning 'odd lots' (fewer than 100 shares), which are more costly to trade.
• The increased proportion of authorized but unissued shares post-Reverse Stock Split could have anti-takeover effects, potentially making it more difficult for a party to obtain control or for stockholders to effect changes in management.
• The issuance of common stock upon conversion of Series B Preferred Stock and exercise of Private Placement Warrants will dilute existing stockholders' ownership and could negatively affect the market price of the common stock.
• Failure to obtain FDA Marketing Authorization for the Product in the United States by June 30, 2026, as required by the Omnibus Amendment, could trigger a Specified Breach Event under the Series B Preferred Stock terms, granting RTW additional director nomination rights and increasing the dividend rate on Series B Preferred Stock.
• Failure to maintain a minimum aggregate balance of $3.0 million in unrestricted cash could also trigger a Specified Breach Event under the Series B Preferred Stock terms.

Future Outlook

The company anticipates that the proposed increase in the equity incentive plan's share pool will be sufficient to provide incentives for attracting, retaining, and motivating employees for the near future. The Board believes the Option Repricing will restore incentive value and improve morale, supporting the company's focus on stock price recovery and growth. The debt-to-equity conversion is a significant step towards regaining compliance with NYSE listing requirements and utilizing cash for working capital. The Reverse Stock Split is intended to broaden investor appeal and maintain NYSE listing, though its long-term effect on trading price cannot be predicted with certainty. The company is also working towards obtaining FDA Marketing Authorization for its product in the U.S. by June 30, 2026.

Management Comments

• "On behalf of the Board of Directors and management of Allurion Technologies, Inc., I cordially invite you to attend our annual meeting of stockholders on December 18, 2025 at 12:00 p.m. Eastern Time." Shantanu Gaur, President and Chief Executive Officer.
• "Our Board of Directors believes that the proposed share pool increase and related changes to the 2023 Plan are reasonable, appropriate, and in the best interests of our stockholders." Board of Directors.
• "As of the Record Date, there are only 249,999 shares of common stock remaining available for issuance under the 2023 Plan, and our Board of Directors believes this amount is insufficient to meet our future needs for attracting, motivating and retaining employees in a competitive market for talent, particularly in light of the lack of any retentive holding power in the Company’s outstanding equity awards to its named executive officers and other key employees." Board of Directors.
• "The Board believes that the Option Repricing is in the best interests of the Company and our stockholders, as it provides incentives to retain and motivate the Eligible Optionholders without incurring (i) the stock dilution that would result from significant additional equity grants or (ii) additional cash expenditures that would result from additional cash compensation." Board of Directors.
• "The Board ultimately determined that the Option Repricing would be the most effective tool in obtaining our objective of realigning interests of the Eligible Optionholders with those of our stockholders because it provides a direct and straightforward means of resetting the incentive value of the Eligible Options." Board of Directors.
• "The Board and the Disinterested Directors additionally determined that the Exchange Agreement, the issuance of the Series B Preferred Stock, and the common stock that may be issued thereby, are in the best interests of the Company and our stockholders because (i) the corresponding increase in our stockholders equity that will result from the exchange of the Notes for the Series B Preferred Stock, and the contribution of that additional stockholders equity toward gaining compliance with the minimum stockholders equity requirement of the NYSE and/or the minimum stockholders equity requirement for initial listing of our common stock on an alternative national securities exchange; and (ii) the extinguishment of the Notes and revenue interest payments will allow us to utilize the cash otherwise needed to repay the Notes and revenue interest payments for working capital." Board of Directors.

Industry Context

Allurion Technologies operates in the medical device manufacturing industry, specifically in the obesity management space. The company faces intense competition for experienced and talented individuals with critical and high-demand skills. The strategic moves outlined in the filing, such as equity incentives and debt restructuring, are aimed at strengthening the company's financial position and market perception within this competitive landscape, particularly as it seeks to expand its product commercialization, including obtaining FDA authorization in the U.S.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance or proposals against global industry benchmarks.

Management Changes

Corporate Governance

Related Party Transactions

• PIPE Investment: Michael Davin (director), Omar Ishrak (director), and RTW (5%+ holder, director designator) subscribed for shares of common stock in a private placement totaling $37.9 million.
• Gaur Contribution Agreement: The Shantanu K. Gaur Revocable Trust of 2021 (affiliated with CEO Shantanu Gaur) contributed 3,170 shares of common stock as capital.
• RSU Forfeiture Agreement: Krishna Gupta (director) forfeited 3,170 restricted stock units.
• 2023 Convertible Note Incremental Financing: Hunter Ventures Limited (HVL), affiliated with director Krishna Gupta, received a $13.0 million convertible bridge note, later terminated with 15,508 additional shares of common stock issued to HVL.
• Revenue Interest Financing Agreements (First and Second RIFA): RTW entities provided $40.0 million and $7.5 million in financing, respectively, in exchange for revenue interest payments (6% to 12% of annual net sales).
• Amended Note Purchase Agreement: $48 million aggregate principal amount of convertible senior secured notes issued to RTW entities, granting RTW director designation rights.
• Omnibus Amendment: Modified terms of the Amended Note Purchase Agreement and RIFAs, including minimum cash balance and revenue covenants, FDA marketing authorization deadlines, and RTW's right to designate two directors (Nicholas Lewin and R. Jason Richey).
• July 2024 Public Offering and Concurrent Private Placement: RTW purchased 9,594 shares of common stock and warrants for $0.3 million. Funds affiliated with RTW also purchased Series A Preferred Stock (converted to 90,407 common shares) and private warrants for $2.7 million.
• January 2025 RTW Private Placement: Funds affiliated with RTW purchased 841,751 shares of common stock for approximately $2.5 million.
• November 2025 Private Placement: Funds managed by RTW purchased 2,994,012 shares of common stock and accompanying warrants for approximately $3.1 million (part of a total $5.0 million gross proceeds).
• Exchange Agreement (November 11, 2025): RTW agreed to exchange all principal amount of Notes and obligations under the First and Second RIFAs for shares of Series B Preferred Stock, with modified director designation rights for RTW.
• Consulting Agreements: KKG Enterprises and Remus Group Management (affiliated with director Krishna Gupta) received $0.2 million and $0.3 million, respectively, for AI platform and advisory services, terminated in June 2023.
• Allurion Middle East Medical Instruments Trading, LLC: A subsidiary where Shuraa Management & Consultancy LLC (UAE entity) holds 51% ownership, and Allurion holds 49%, with profit distribution of 20% to Shuraa and 80% to Allurion. Lease agreements with SBCB, an affiliate of Shuraa.
• Corporate Officer Agreement and Termination Agreement: Benoit Chardon (former Chief Commercial Officer) and his solely-owned company, Benoit Chardon Consulting (BCC), received consulting fees and a lump-sum termination fee of 156,740.

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of shares for the amended equity plan, debt conversion, and warrant exercises. The Reverse Stock Split aims to improve market perception and liquidity but may also lead to negative sentiment or increased trading costs for odd lots. Voting power will be affected by new issuances and the potential for RTW to gain additional director nomination rights.
• Employees: The amended equity plan and option repricing are designed to restore incentive and retention value, improving morale and motivation, especially given the prior freeze on cash bonuses and base salaries.
• Creditors (specifically RTW): Will convert significant debt and revenue interest obligations into equity (Series B Preferred Stock), shifting their position from creditor to a major equity holder with enhanced governance rights.
• Company Management: Will gain increased flexibility in attracting and retaining talent through the amended equity plan. The debt restructuring will free up cash for working capital, aiding operational initiatives.

Next Steps

• Stockholders to vote on eight proposals at the Annual Meeting on December 18, 2025.
• If approved, the Board will determine the exact ratio and effective time for the Reverse Stock Split within one year of approval.
• The company will file a Current Report on Form 8-K with the SEC to report the final voting results after the Annual Meeting.
• The company is obligated to use its best efforts to obtain FDA Marketing Authorization for its product in the United States no later than June 30, 2026.
• If stockholder approval for the Private Placement Warrant Shares Issuance is not obtained, the company must call a meeting every 60 days thereafter to seek such approval until the warrants are no longer outstanding.

Key Dates

Recommendation

The company is undertaking a series of significant strategic and financial maneuvers, including a reverse stock split, a comprehensive equity plan amendment, option repricing, and a substantial debt-to-equity conversion. These actions are primarily aimed at addressing critical issues such as NYSE listing compliance, employee retention, and balance sheet health. While these are proactive steps to stabilize the company and position it for future growth, their ultimate success and impact on long-term shareholder value are uncertain. The potential for further dilution and the inherent risks associated with such large-scale changes warrant a 'hold' recommendation, advising investors to monitor the execution of these proposals and their subsequent effects on the company's financial performance and market position before making further investment decisions.

Keywords

Allurion Technologies, ALUR, Proxy Statement, Reverse Stock Split, Stock Option Plan, Debt Conversion, NYSE Listing, Corporate Governance, Equity Incentive, Shareholder Meeting, Option Repricing, Preferred Stock, Warrants